Evaluating a Structured Reporting Template to Increase Transparency and Reduce Review Time for Healthcare Database Studies

Focus Groups as Used by the Food and Drug Administration

Appendix B1 - Structured Reporting Template

Evaluating a Structured Reporting Template to Increase Transparency and Reduce Review Time for Healthcare Database Studies

OMB: 0910-0497

Document [docx]
Download: docx | pdf

OMB Control No. 0910-0497 Expiration date: 10/31/2020


Appendix B1: Structured Reporting Template (word version)

TABLE OF CONTENTS

Administrative Information

Version History

Design Diagram

Attrition Table

Power Calculation

Analysis Specification

Glossary of Terminology

 

APPENDICES (with details of algorithms)

A - Study Population Entry Criteria (Exposure)

B - Drug, Diagnosis, and Procedure-Based Inclusion/Exclusion Criteria

C - Drug, Diagnosis, and Procedure-Based Covariates

D - Outcome

E - Care Setting



VERSION HISTORY

Version Date

Version Number

Change Log

Rationale for Change

November 12, 2018

v2

Added covariate: "co-prescription of Drug C" measured in days [-183, 0] in any care setting and diagnosis position

Added because of concern that Drug C may interact with effect of Drug A and B

April 15, 2019

v3

Changed covariate assessment window from days [-183, -1] to [-183, 0]

Changed assessment window to include day 0, due to concern that important diagnoses occurring on the day of drug dispensation may be missed













ATTRITION TABLE

 

 

 

Less Excluded Patients

Remaining Patients

All patients

 

 

Did not meet cohort entry criteria (dispensation of drug A or drug B)

 

 

Excluded due to insufficient prior enrollment (<183 days with 45-day gaps allowed)

 

 

Excluded due to prior use of referent (Drug B)

 

 

Excluded due to prior use of exposure (Drug A)

 

 

Excluded because patient qualified in >1 exposure category

 

 

Excluded based on Age <18

 

 

Excluded based on Age ≥65

 

 

Excluded based on Gender (unknown)

 

 

Excluded based on Drug supply <=0 days

 

 

Excluded based on Drug A (additional formulations and combinations not included in exposure)

 

 

Excluded based on Drug B (additional formulations and combinations not included in referent)

 

 

Excluded based on absence of community acquired pneumonia diagnosis within 14 days prior to index date

 

 

Excluded based on absence of chest x-ray within 14 days prior to index date

 

 

Excluded based on inpatient admission within 90 days prior to index date

 

 

Excluded if censored on day 1

 

 

Final cohort

 

 

 

Drug A initiators
N =

 

 

Drug B initiators
N =

 







ANALYSIS SPECIFICATIONS

 

 

 

 

 

Analyses

 

 

 

 

 

 

Primary

Secondary 1

Secondary 2

Subgroup

Sensitivity

Outcome:

Myocardial infarction

Stroke

TIA

n/a

Myocardial infarction

Software:

SAS 9.4: PHREG, PROC LOGISTIC, Pharmacoepi Toolbox nearest neighbor matching macro (http://www.drugepi.org/dope-downloads/)

SAS 9.4: PHREG, PROC LOGISTIC, Pharmacoepi Toolbox nearest neighbor matching macro (http://www.drugepi.org/dope-downloads/)

SAS 9.4: PHREG, PROC LOGISTIC, Pharmacoepi Toolbox nearest neighbor matching macro (http://www.drugepi.org/dope-downloads/)

 

SAS 9.4: PHREG, PROC LOGISTIC, Pharmacoepi Toolbox nearest neighbor matching macro (http://www.drugepi.org/dope-downloads/)

Model(s):

Outcome: Cox proportional hazards model,
Propensity score: logistic regression

Outcome: Cox proportional hazards model,
Propensity score: logistic regression

Outcome: Cox proportional hazards model,
Propensity score: logistic regression

 

Outcome: Cox proportional hazards model,
Propensity score: logistic regression

Confounding Adjustment
(check all that apply and provide details, where requested)

 

 

 

 

 

Bivariate

 

 

 

 

 

Multivariable

 

 

 

 

 

Propensity Score Matching

X

X

X

 

 

(specify matching algorithm, ratio, and caliper)

Nearest neighbor, Ratio = fixed 1:1, Caliper = 0.025

Nearest neighbor, Ratio = fixed 1:1, Caliper = 0.025

Nearest neighbor, Ratio = fixed 1:1, Caliper = 0.025

 

 

Propensity Score Weighting

 

 

 

 

X

Confounding Adjustment
(check all that apply and provide details, where requested)






(specify weight formula, trimming, truncation decisions)

 

 

 

 

Exposed weight = 1, Comparator weight = PS/(1-PS), 1% asymmetrical trim

Propensity Score Stratification

 

 

 

 

 

(specify strata definition)

 

 

 

 

 

Other

 

 

 

 

 

(specify details)

 

 

 

 

 

Missing Data Methods (check all that apply)

 

 

 

 

 

Missing Indicators

 

 

 

 

 

Complete Case

 

 

 

 

 

Last Value Carried Forward

 

 

 

 

 

Multiple Imputation

 

 

 

 

 

Other (please specify)…

 

 

 

 

 









GLOSSARY

 

Term

Definition

Confounder

Variable other than the exposure of interest or outcome under investigation that is: 1) associated with exposure; 2) a risk factor for the outcome; and 3) not on the causal pathway between the exposure and the outcome. A confounder can artificially inflate or reduce the magnitude of association between an exposure and outcome.

Covariates

Variables that are neither exposure nor outcome of interest but are measured to describe a population or because they may be a confounder to account for in analyses.

Data Extraction Date

The date when the data were extracted from the dynamic healthcare database.

Days Supplied

Number of days supplied for a dispensed prescription.

Eligible Cohort Entry Period

Calendar time frame, during which cohort entry dates are identified.

Empirically-Defined Covariates

Covariates that are not prespecified by the investigator. The selection of these covariates is based on applying algorithms to the data. The algorithms for covariate selection may be tuned by investigator-specified parameters.

Enrollment/Coverage

For insurance claims data, this may refer to periods of enrollment in medical and/or drug plans. For electronic health record databases, this may refer to algorithms designed to identify patients whose healthcare contacts are likely to be covered within the healthcare system.

Enrollment Gap

Maximum number of days allowed between two consecutive enrollment periods to still be considered “continuously enrolled.”

Follow-Up Window

The interval during which occurrence of the outcome of interest in the study population will be included in the analysis.

Grace Window

Number of days added to days’ supply to allow for non-adherence or account for the hypothesized biologic exposure risk window. Operationally, this could be defined as the number of extra days added to the end of a days’ supply to extend time counted as "exposed." This grace may bridge the gap between dispensations, where the days’ supply dispensed does not cover all days until the refill.

Index Date

The date when subjects enter the study population (cohort entry date, outcome event date). It is defined based on events in the patient's longitudinal timeline; other windows are defined relative to the index date.

Assessment Window

Interval during which a patient is required to have evidence of a pre-existing condition (diagnosis/procedure/drug dispensing). May be used for washout of exposure or outcome, exclusion assessment, or covariate assessment.

Predefined Covariates

Covariates that are prespecified and defined by the investigator in the protocol.

Principal Diagnosis

Diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital.

Source Data Range

The calendar time range covered by a data source that is available.

Stockpiling Algorithm

Algorithm defining how early refills are handled when determining length of exposure follow up.

Study Period

Calendar time interval of data available for study, including pre-index date assessment windows and post-index follow up.

Treatment Episode

Continuous period of exposure, defined by using dispensation date + days’ supply and applying stockpiling algorithms and/or grace windows.

Washout Window

Minimum number of days a patient is required to have no evidence of prior exposure and/or outcome.

Wildcard

Symbol used to represent any single alphanumeric digit in code algorithms. For example, 410.*1, where * is the wildcard.





Appendix A: Study Population Entry Criteria

Study Entry Criterion

NDC

Generic Name

Brand Name

Route

Strength

Drug A

00003016050

drug A

Awesome Drug

tablet

250mg

Drug B

00003016050

drug B

Really Cool Drug

tablet

250mg











Appendix B: Drug, Diagnosis, and Procedure-Based Inclusion/Exclusion Criteria

Exclusion Criteria

Code

Code Category

Code Type

Description

Route

Strength

Drug A

00003016050

drug A

NDC

Awesome Drug

tablet

250mg

Drug B

00003016050

drug B

NDC

Really Cool Drug

tablet

250mg

Drug A

01003016050

drug A

NDC

Awesome Drug oral

oral suspension

5 ml

Drug B

00803016050

drug B

NDC

Really Cool Drug injectable

injectable

5 y injectable

Chest radiography

87.44

PX

09

Routine chest x-ray, so described



Chest radiography

87.49

PX

09

Other chest x-ray



Chest radiography

71010

PX

C4

Radiologic examination, chest; single view, frontal



Chest radiography

71015

PX

C4

Radiologic examination, chest; stereo, frontal



Chest radiography

71020

PX

C4

Radiologic examination, chest, 2 views, frontal and lateral / Radiologic examination, chest, 2 views, frontal and lateral; / Radiologic examination, chest, two views, frontal and lateral



Chest radiography

71021

PX

C4

Radiologic examination, chest, 2 views, frontal and lateral; with apical lordotic procedure / Radiologic examination, chest, two views, frontal and lateral; with apical lordotic procedure



Chest radiography

71022

PX

C4

Radiologic examination, chest, 2 views, frontal and lateral; with oblique projections / Radiologic examination, chest, two views, frontal and lateral; with oblique projections



Chest radiography

71023

PX

C4

Radiologic examination, chest, 2 views, frontal and lateral; with fluoroscopy / Radiologic examination, chest, two views, frontal and lateral; with fluoroscopy



Chest radiography

71030

PX

C4

Radiologic examination, chest, complete, minimum of 4 views / Radiologic examination, chest, complete, minimum of 4 views; / Radiologic examination, chest, complete, minimum of four views



Chest radiography

71034

PX

C4

Radiologic examination, chest, complete, minimum of 4 views; with fluoroscopy / Radiologic examination, chest, complete, minimum of four views; with fluoroscopy



Chest radiography

71035

PX

C4

Radiologic examination, chest, special views (e.g., lateral decubitus, Bucky studies)



Community-acquired pneumonia

480

DX

09

VIRAL PNEUMONIA



Community-acquired pneumonia

480.0

DX

09

PNEUMONIA DUE TO ADENOVIRUS



Community-acquired pneumonia

480.1

DX

09

PNEUMONIA DUE TO RESPIRATORY SYNCYTIAL VIRUS



Community-acquired pneumonia

480.2

DX

09

PNEUMONIA DUE TO PARAINFLUENZA VIRUS



Community-acquired pneumonia

480.3

DX

09

PNEUMONIA DUE TO SARS-ASSOCIATED CORONAVIRUS



Community-acquired pneumonia

480.8

DX

09

PNEUMONIA DUE TO OTHER VIRUS NOT ELSEWHERE CLASSIFIED



Community-acquired pneumonia

480.9

DX

09

VIRAL PNEUMONIA UNSPECIFIED



Community-acquired pneumonia

481

DX

09

PNEUMOCOCCAL PNEUMONIA [STREPTOCOCCUS PNEUMONIAE PNEUMONIA]



Community-acquired pneumonia

482

DX

09

OTHER BACTERIAL PNEUMONIA



Community-acquired pneumonia

482.0

DX

09

PNEUMONIA DUE TO KLEBSIELLA PNEUMONIAE



Community-acquired pneumonia

482.1

DX

09

PNEUMONIA DUE TO PSEUDOMONAS



Community-acquired pneumonia

482.2

DX

09

PNEUMONIA DUE TO HEMOPHILUS INFLUENZAE (H. INFLUENZAE)



Community-acquired pneumonia

482.3

DX

09

PNEUMONIA DUE TO STREPTOCOCCUS



Community-acquired pneumonia

482.30

DX

09

PNEUMONIA DUE TO STREPTOCOCCUS UNSPECIFIED



Community-acquired pneumonia

482.31

DX

09

PNEUMONIA DUE TO STREPTOCOCCUS GROUP A



Community-acquired pneumonia

482.32

DX

09

PNEUMONIA DUE TO STREPTOCOCCUS GROUP B



Community-acquired pneumonia

482.39

DX

09

PNEUMONIA DUE TO OTHER STREPTOCOCCUS



Community-acquired pneumonia

482.4

DX

09

PNEUMONIA DUE TO STAPHYLOCOCCUS



Community-acquired pneumonia

482.40

DX

09

PNEUMONIA DUE TO STAPHYLOCOCCUS UNSPECIFIED



Community-acquired pneumonia

482.41

DX

09

METHICILLIN SUSCEPTIBLE PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS



Community-acquired pneumonia

482.42

DX

09

METHICILLIN RESISTANT PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS



Community-acquired pneumonia

482.49

DX

09

OTHER STAPHYLOCOCCUS PNEUMONIA



Community-acquired pneumonia

482.8

DX

09

PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA



Community-acquired pneumonia

482.81

DX

09

PNEUMONIA DUE TO ANAEROBES



Community-acquired pneumonia

482.82

DX

09

PNEUMONIA DUE TO ESCHERICHIA COLI [E.COLI]



Community-acquired pneumonia

482.83

DX

09

PNEUMONIA DUE TO OTHER GRAM-NEGATIVE BACTERIA



Community-acquired pneumonia

482.84

DX

09

PNEUMONIA DUE TO LEGIONNAIRES' DISEASE



Community-acquired pneumonia

482.89

DX

09

PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA



Community-acquired pneumonia

482.9

DX

09

BACTERIAL PNEUMONIA UNSPECIFIED



Community-acquired pneumonia

483

DX

09

PNEUMONIA DUE TO OTHER SPECIFIED ORGANISM



Community-acquired pneumonia

483.0

DX

09

PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE



Community-acquired pneumonia

483.1

DX

09

PNEUMONIA DUE TO CHLAMYDIA



Community-acquired pneumonia

483.8

DX

09

PNEUMONIA DUE TO OTHER SPECIFIED ORGANISM



Community-acquired pneumonia

484

DX

09

PNEUMONIA IN INFECTIOUS DISEASES CLASSIFIED ELSEWHERE



Community-acquired pneumonia

484.1

DX

09

PNEUMONIA IN CYTOMEGALIC INCLUSION DISEASE



Community-acquired pneumonia

484.3

DX

09

PNEUMONIA IN WHOOPING COUGH



Community-acquired pneumonia

484.5

DX

09

PNEUMONIA IN ANTHRAX



Community-acquired pneumonia

484.6

DX

09

PNEUMONIA IN ASPERGILLOSIS



Community-acquired pneumonia

484.7

DX

09

PNEUMONIA IN OTHER SYSTEMIC MYCOSES



Community-acquired pneumonia

484.8

DX

09

PNEUMONIA IN OTHER INFECTIOUS DISEASES CLASSIFIED ELSEWHERE



Community-acquired pneumonia

485

DX

09

BRONCHOPNEUMONIA ORGANISM UNSPECIFIED



Community-acquired pneumonia

486

DX

09

PNEUMONIA ORGANISM UNSPECIFIED



Community-acquired pneumonia

487

DX

09

INFLUENZA



Community-acquired pneumonia

487.0

DX

09

INFLUENZA WITH PNEUMONIA



Community-acquired pneumonia

487.1

DX

09

INFLUENZA WITH OTHER RESPIRATORY MANIFESTATIONS



Community-acquired pneumonia

487.8

DX

09

INFLUENZA WITH OTHER MANIFESTATIONS



Community-acquired pneumonia

038.0

DX

09

STREPTOCOCCAL SEPTICEMIA



Community-acquired pneumonia

038.2

DX

09

PNEUMOCOCCAL SEPTICEMIA



Community-acquired pneumonia

041.0

DX

09

STREPTOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE



Community-acquired pneumonia

041.00

DX

09

STREPTOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE STREPTOCOCCUS UNSPECIFIED



Community-acquired pneumonia

041.01

DX

09

STREPTOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE STREPTOCOCCUS GROUP A



Community-acquired pneumonia

041.02

DX

09

STREPTOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE STREPTOCOCCUS GROUP B



Community-acquired pneumonia

041.03

DX

09

STREPTOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE STREPTOCOCCUS GROUP C



Community-acquired pneumonia

041.04

DX

09

STREPTOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE STREPTOCOCCUS GROUP D [ENTEROCOCCUS]



Community-acquired pneumonia

041.05

DX

09

STREPTOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE STREPTOCOCCUS GROUP G



Community-acquired pneumonia

041.09

DX

09

STREPTOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE OTHER STREPTOCOCCUS



Community-acquired pneumonia

041.2

DX

09

PNEUMOCOCCUS INFECTION IN CONDITIONS CLASSIFIED ELSEWHERE AND OF UNSPECIFIED SITE



Community-acquired pneumonia

320.1

DX

09

PNEUMOCOCCAL MENINGITIS







Appendix C: Drug, Diagnosis, and Procedures, Based on Covariates

(Note: as the file is extensive, we provide the first few covariates, here, only; for the full list, please visit the excel document).

Covariate

Code

Code Category

Code Type

Description

Strength

Dose

Degenerative disease of central nervous system

330

DX

09

CEREBRAL DEGENERATIONS USUALLY MANIFEST IN CHILDHOOD



Degenerative disease of central nervous system

330.0

DX

09

LEUKODYSTROPHY



Degenerative disease of central nervous system

330.1

DX

09

CEREBRAL LIPIDOSES



Degenerative disease of central nervous system

330.2

DX

09

CEREBRAL DEGENERATION IN GENERALIZED LIPIDOSES



Degenerative disease of central nervous system

330.3

DX

09

CEREBRAL DEGENERATION OF CHILDHOOD IN OTHER DISEASES

CLASSIFIED ELSEWHERE



Degenerative disease of central nervous system

330.8

DX

09

OTHER SPECIFIED CEREBRAL DEGENERATIONS IN CHILDHOOD



Degenerative disease of central nervous system

330.9

DX

09

UNSPECIFIED CEREBRAL DEGENERATION IN CHILDHOOD



Degenerative disease of central nervous system

331

DX

09

OTHER CEREBRAL DEGENERATIONS



Degenerative disease of central nervous system

331.0

DX

09

ALZHEIMER'S DISEASE



Degenerative disease of central nervous system

331.1

DX

09

FRONTOTEMPORAL DEMENTIA



Degenerative disease of central nervous system

331.11

DX

09

PICK'S DISEASE



Degenerative disease of central nervous system

331.19

DX

09

OTHER FRONTOTEMPORAL DEMENTIA



Degenerative disease of central nervous system

331.2

DX

09

SENILE DEGENERATION OF BRAIN



Degenerative disease of central nervous system

331.3

DX

09

COMMUNICATING HYDROCEPHALUS



Degenerative disease of central nervous system

331.4

DX

09

OBSTRUCTIVE HYDROCEPHALUS



Degenerative disease of central nervous system

331.5

DX

09

IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS (INPH)



Degenerative disease of central nervous system

331.6

DX

09

CORTICOBASAL DEGENERATION



Degenerative disease of central nervous system

331.7

DX

09

CEREBRAL DEGENERATION IN DISEASES CLASSIFIED ELSEWHERE



Degenerative disease of central nervous system

331.8

DX

09

OTHER CEREBRAL DEGENERATION



Degenerative disease of central nervous system

331.81

DX

09

REYE'S SYNDROME



Degenerative disease of central nervous system

331.82

DX

09

DEMENTIA WITH LEWY BODIES



Degenerative disease of central nervous system

331.83

DX

09

MILD COGNITIVE IMPAIRMENT SO STATED



Degenerative disease of central nervous system

331.89

DX

09

OTHER CEREBRAL DEGENERATION



Degenerative disease of central nervous system

331.9

DX

09

CEREBRAL DEGENERATION UNSPECIFIED



Degenerative disease of central nervous system

332

DX

09

PARKINSON'S DISEASE



Degenerative disease of central nervous system

332.0

DX

09

PARALYSIS AGITANS



Degenerative disease of central nervous system

332.1

DX

09

SECONDARY PARKINSONISM



Degenerative disease of central nervous system

333

DX

09

OTHER EXTRAPYRAMIDAL DISEASE AND ABNORMAL MOVEMENT

DISORDERS



Degenerative disease of central nervous system

333.0

DX

09

OTHER DEGENERATIVE DISEASES OF THE BASAL GANGLIA



Degenerative disease of central nervous system

333.1

DX

09

ESSENTIAL AND OTHER SPECIFIED FORMS OF TREMOR



Degenerative disease of central nervous system

333.2

DX

09

MYOCLONUS



Degenerative disease of central nervous system

333.3

DX

09

TICS OF ORGANIC ORIGIN



Degenerative disease of central nervous system

333.4

DX

09

HUNTINGTON'S CHOREA



Degenerative disease of central nervous system

333.5

DX

09

OTHER CHOREAS



Degenerative disease of central nervous system

333.6

DX

09

GENETIC TORSION DYSTONIA



Degenerative disease of central nervous system

333.7

DX

09

ACQUIRED TORSION DYSTONIA



Degenerative disease of central nervous system

333.71

DX

09

ATHETOID CEREBRAL PALSY



Degenerative disease of central nervous system

333.72

DX

09

ACUTE DYSTONIA DUE TO DRUGS



Degenerative disease of central nervous system

333.79

DX

09

OTHER ACQUIRED TORSION DYSTONIA



Degenerative disease of central nervous system

333.8

DX

09

FRAGMENTS OF TORSION DYSTONIA



Degenerative disease of central nervous system

333.81

DX

09

BLEPHAROSPASM



Degenerative disease of central nervous system

333.82

DX

09

OROFACIAL DYSKINESIA



Degenerative disease of central nervous system

333.83

DX

09

SPASMODIC TORTICOLLIS







Appendix D: Outcome


Outcome

Code

Code Category

Code Type

Description

Myocardial Infarction

41001

DX

ICD9

Acute myocardial infarction of anterolateral wall, initial episode of care



















Appendix E: Care Setting



CARE SETTING



IP = inpatient

All claims in the MarketScan inpatient admissions table and inpatient services are coded as IP; primary diagnosis is defined by the inpatient admissions primary diagnosis, only.


ED = emergency department

Any encounters in the inpatient service or outpatient service table with SVCSCAT ending in '20' or STDPLAC in ('23', '41', 42').


AV = ambulatory visit

Based on outpatient service table values for STDPLAC (see below).


IS = institutional stay

Based on outpatient service table values for STDPLAC (see below).


OA = other ambulatory visit

Based on outpatient service table values for STDPLAC (see below).


STDPLAC



Value

Label

Care Setting

1

Pharmacy

AV

3

School

AV

4

Homeless Shelter

AV

11

Office

AV

12

Patient Home

AV

13

Assisted Living Facility

IS

14

Group Home

IS

15

Mobile Unit

AV

16

Temporary Lodging

AV

17

Walk-In Retail Health Clinic

AV

18

Place of Employment - Worksite

AV

20

Urgent Care Facility

AV

21

Inpatient Hospital

AV

22

Outpatient Hospital

AV

23

Emergency Room - Hospital

ED

24

Ambulatory Surgical Center

AV

25

Birthing Center

AV

26

Military Treatment Facility

AV

Value

Label

Care Setting

27

Inpatient Long-Term Care (NEC)

IS

28

Other Inpatient Care (NEC)

IS

31

Skilled Nursing Facility

IS

32

Nursing Facility

IS

33

Custodial Care Facility

IS

34

Hospice

IS

35

Adult Living Care Facility

IS

41

Ambulance (land)

ED

42

Ambulance (air or water)

ED

49

Independent Clinic

AV

50

Federally Qualified Health Center

AV

51

Inpatient Psychiatric Facility

AV

52

Psych Facility Partial Hospital

AV

53

Community Mental Health Center

AV

54

Intermed Care/Mental Retarded

AV

55

Residential Substance Abuse Facility

AV

56

Psych Residential Treatment Center

AV

57

Non-Resident Substance Abuse Facility

AV

60

Mass Immunization Center

AV

61

Comprehensive Inpatient Rehab Facility

AV

62

Comprehensive Outpatient Rehab Facility

AV

65

End-Stage Renal Disease Facility

AV

71

State/Local Public Health Clinic

AV

72

Rural Health Clinic

AV

81

Independent Laboratory

AV

95

Outpatient (NEC)

AV

98

Pharmacy

AV

99

Other Unlisted Facility

OA



78 | Page


File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorPinheiro, Simone P
File Modified0000-00-00
File Created2021-01-15

© 2024 OMB.report | Privacy Policy